Small‐molecule STING inhibitors such as H‐151 have demonstrated efficacy in various preclinical models of lung disease, including LPS‐induced acute lung injury,[61] radiation‐induced pneumonitis,[62] and steroid‐resistant asthma.[63] Moreover, restoring RNASEH1 function, either through mRNA delivery or small‐molecule activators, could suppress upstream R‐loop accumulation and potentially attenuate inflammation at its source. Here, STING1 is linked to injury.